A randomised, placebo-controlled study of omipalisib (PI3K/mTOR) in idiopathic pulmonary fibrosis

Phosphatidylinositol 3-kinases (PI3Ks) and mammalian target of rapamycin (mTOR) play a role in the pathogenesis of idiopathic pulmonary fibrosis (IPF). Omipalisib (GSK2126458) is a potent inhibitor of PI3K/mTOR.A randomised, placebo-controlled, double-blind, repeat dose escalation, experimental medi...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	The European respiratory journal 2019-03, Vol.53 (3), p.1801992
Hauptverfasser:	Lukey, Pauline T, Harrison, Stephen A, Yang, Shuying, Man, Yim, Holman, Beverley F, Rashidnasab, Alaleh, Azzopardi, Gabrielle, Grayer, Michael, Simpson, Juliet K, Bareille, Philippe, Paul, Lyn, Woodcock, Hannah V, Toshner, Richard, Saunders, Peter, Molyneaux, Philip L, Thielemans, Kris, Wilson, Frederick J, Mercer, Paul F, Chambers, Rachel C, Groves, Ashley M, Fahy, William A, Marshall, Richard P, Maher, Toby M
Format:	Artikel
Sprache:	eng
Schlagworte:	Administration, Oral Aged Dose-Response Relationship, Drug Double-Blind Method Female Fluorodeoxyglucose F18 Humans Idiopathic Pulmonary Fibrosis - diagnostic imaging Idiopathic Pulmonary Fibrosis - drug therapy Lung - diagnostic imaging Lung - pathology Male Middle Aged Phosphatidylinositol 3-Kinases - metabolism Positron Emission Tomography Computed Tomography Pyridazines Quinolines - administration & dosage Sulfonamides - administration & dosage TOR Serine-Threonine Kinases - metabolism Treatment Outcome
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!